255 related articles for article (PubMed ID: 1328675)
1. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.
Longnecker R; Miller CL; Miao XQ; Marchini A; Kieff E
J Virol; 1992 Nov; 66(11):6461-9. PubMed ID: 1328675
[TBL] [Abstract][Full Text] [Related]
2. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.
Longnecker R; Miller CL; Tomkinson B; Miao XQ; Kieff E
J Virol; 1993 Aug; 67(8):5068-74. PubMed ID: 8392630
[TBL] [Abstract][Full Text] [Related]
3. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.
Longnecker R; Miller CL; Miao XQ; Tomkinson B; Kieff E
J Virol; 1993 Apr; 67(4):2006-13. PubMed ID: 8383224
[TBL] [Abstract][Full Text] [Related]
4. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.
Fruehling S; Lee SK; Herrold R; Frech B; Laux G; Kremmer E; Grässer FA; Longnecker R
J Virol; 1996 Sep; 70(9):6216-26. PubMed ID: 8709248
[TBL] [Abstract][Full Text] [Related]
5. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
Ikeda M; Ikeda A; Longnecker R
J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues.
Kaye KM; Izumi KM; Mosialos G; Kieff E
J Virol; 1995 Feb; 69(2):675-83. PubMed ID: 7815530
[TBL] [Abstract][Full Text] [Related]
7. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation.
Konishi K; Maruo S; Kato H; Takada K
J Gen Virol; 2001 Jun; 82(Pt 6):1451-1456. PubMed ID: 11369890
[TBL] [Abstract][Full Text] [Related]
8. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro.
Tomkinson B; Kieff E
J Virol; 1992 May; 66(5):2893-903. PubMed ID: 1313908
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
Brooks L; Yao QY; Rickinson AB; Young LS
J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
[TBL] [Abstract][Full Text] [Related]
10. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.
Izumi KM; Cahir McFarland ED; Riley EA; Rizzo D; Chen Y; Kieff E
J Virol; 1999 Dec; 73(12):9908-16. PubMed ID: 10559303
[TBL] [Abstract][Full Text] [Related]
11. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).
Rochford R; Miller CL; Cannon MJ; Izumi KM; Kieff E; Longnecker R
Arch Virol; 1997; 142(4):707-20. PubMed ID: 9170499
[TBL] [Abstract][Full Text] [Related]
12. Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture.
Kim OJ; Yates JL
J Virol; 1993 Dec; 67(12):7634-40. PubMed ID: 8230482
[TBL] [Abstract][Full Text] [Related]
13. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.
Miller CL; Lee JH; Kieff E; Longnecker R
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):772-6. PubMed ID: 8290598
[TBL] [Abstract][Full Text] [Related]
14. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.
Kaye KM; Izumi KM; Li H; Johannsen E; Davidson D; Longnecker R; Kieff E
J Virol; 1999 Dec; 73(12):10525-30. PubMed ID: 10559372
[TBL] [Abstract][Full Text] [Related]
15. Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.
Rechsteiner MP; Berger C; Weber M; Sigrist JA; Nadal D; Bernasconi M
J Gen Virol; 2007 May; 88(Pt 5):1454-1459. PubMed ID: 17412973
[TBL] [Abstract][Full Text] [Related]
16. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
17. The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection.
Wasil LR; Tomaszewski MJ; Hoji A; Rowe DT
PLoS One; 2013; 8(1):e54010. PubMed ID: 23308294
[TBL] [Abstract][Full Text] [Related]
18. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
Robertson ES; Tomkinson B; Kieff E
J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
[TBL] [Abstract][Full Text] [Related]
20. A Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, expressed after transformation of primary human B lymphocytes by Epstein-Barr virus (EBV) is induced by the EBV oncogene LMP1.
Mosialos G; Hanissian SH; Jawahar S; Vara L; Kieff E; Chatila TA
J Virol; 1994 Mar; 68(3):1697-705. PubMed ID: 8107230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
